---
figid: PMC2614304__nihms-79970-f0006
figtitle: PCPH/ENTPD5 expression confers to prostate cancer cells resistance against
  cisplatin-induced apoptosis through PKCAlpha-mediated Bcl-2 stabilization
organisms:
- Mus musculus
- Rattus norvegicus
- Mesocricetus auratus
- Homo sapiens
- Saccharomyces cerevisiae
- Oryctolagus cuniculus
- Antarctothoa delta
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC2614304
filename: nihms-79970-f0006.jpg
figlink: /pmc/articles/PMC2614304/figure/F6/
number: F6
caption: PKCα phosphorylates Bcl-2 at serine 70, preventing Bcl-2 from degradation.
  Treatment with cisplatin produces PKCα dephosphorylation or inactivation, which
  decreases the levels of phosphorylation of Bcl-2. The ubiquitin/proteasome pathway
  degrades dephosphorylated Bcl-2. Once the levels of Bcl-2 decrease, the pro-apoptotic
  protein BAX is released activating the apoptotic pathway. The expression of mt-PCPH
  prevents cisplatin-induced PKCα dephosphorylation. Activated PKCα prevents Bcl-2
  degradation. High levels of Bcl-2 protect prostate cancer cells against apoptosis
  induced by cisplatin.
papertitle: PCPH/ENTPD5 expression confers to prostate cancer cells resistance against
  cisplatin-induced apoptosis through PKCα-mediated Bcl-2 stabilization.
reftext: Joaquín Villar, et al. Cancer Res. ;69(1):102-110.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8473764
figid_alias: PMC2614304__F6
figtype: Figure
redirect_from: /figures/PMC2614304__F6
ndex: afebfc9a-deb0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2614304__nihms-79970-f0006.html
  '@type': Dataset
  description: PKCα phosphorylates Bcl-2 at serine 70, preventing Bcl-2 from degradation.
    Treatment with cisplatin produces PKCα dephosphorylation or inactivation, which
    decreases the levels of phosphorylation of Bcl-2. The ubiquitin/proteasome pathway
    degrades dephosphorylated Bcl-2. Once the levels of Bcl-2 decrease, the pro-apoptotic
    protein BAX is released activating the apoptotic pathway. The expression of mt-PCPH
    prevents cisplatin-induced PKCα dephosphorylation. Activated PKCα prevents Bcl-2
    degradation. High levels of Bcl-2 protect prostate cancer cells against apoptosis
    induced by cisplatin.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Entpd5
  - Elf1
  - Il2rb
  - Ubash3b
  - Prkca
  - Bcl2
  - Casp3
  - ENTPD5
  - ANXA6
  - UBASH3B
  - PRKCA
  - BCL2
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - WDR79
  - tral
  - rump
  - MED17
  - SF1
  - Irbp
  - Debcl
  - Decay
  - Cisplatin
---
